(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 31.61% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Alvotech's revenue in 2025 is $562,478,000.On average, 2 Wall Street analysts forecast ALVO's revenue for 2025 to be $204,537,801,896, with the lowest ALVO revenue forecast at $197,866,732,790, and the highest ALVO revenue forecast at $211,209,182,603. On average, 1 Wall Street analysts forecast ALVO's revenue for 2026 to be $296,840,295,734, with the lowest ALVO revenue forecast at $296,840,295,734, and the highest ALVO revenue forecast at $296,840,295,734.
In 2027, ALVO is forecast to generate $401,902,856,828 in revenue, with the lowest revenue forecast at $401,902,856,828 and the highest revenue forecast at $401,902,856,828.